v3.26.3
Marketable Securities - Schedule of Marketable Securities Include Investments in Equity Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Short -term:    
Short-term marketable securities $ 583 $ 5,417
Long-term:    
Long-term marketable securities 10,801 8,371
DNA [Member]    
Short -term:    
Short-term marketable securities [1] 583 540
Entera [Member]    
Short -term:    
Short-term marketable securities [2] 227
Pelthos [Member]    
Short -term:    
Short-term marketable securities [3] 4,650
Nano [Member]    
Long-term:    
Long-term marketable securities [4],[5] $ 10,801 $ 8,371
[1] As of September 30, 2026, the Company held 1,701,357 ordinary shares of DNA, representing approximately 0.18% of DNA’s issued and outstanding ordinary shares.
[2] During the nine months ended September 30, 2026, the Company sold 117,000 shares of Entera common stock for aggregate proceeds of $176. As a result, as of September 30, 2026, the Company no longer holds any shares of Entera common stock.
[3] During the nine months ended September 30, 2026, the Company sold 150,000 shares of Pelthos common stock for aggregate proceeds of $3,625. As a result, as of September 30, 2026, the Company no longer holds any shares of Pelthos common stock.
[4] During the nine months ended September 30, 2026, the Company purchased 12,738,504 ordinary shares for an aggregate purchase price of $20,896 and sold 11,295,587 shares of Nano common stock for aggregate proceeds of $18,548. As of September 30, 2026, the Company held 6,879,708 ordinary shares of Nano, representing approximately 3.26% of Nano’s issued and outstanding ordinary shares.
[5] During the nine months ended September 30, 2026, the Company entered into put and call option transactions on Nano ordinary shares. The Company paid aggregate premiums of $3,336 for the purchase of put options and $1,570 for the repurchase of written call options, and received aggregate premiums of $2,644 from writing call options and aggregate proceeds of $1,303 from the sale of put options. All option positions were closed during the period and, accordingly, no options were outstanding as of December 31, 2025 or September 30, 2026. The Company recognized a net loss of $959 in respect of these options, which is included in the loss related to marketable securities within “financial income, net”.